CN116103280B - 样本保存液及其在染色体非整倍体筛查和/或转录组检测中的应用 - Google Patents
样本保存液及其在染色体非整倍体筛查和/或转录组检测中的应用 Download PDFInfo
- Publication number
- CN116103280B CN116103280B CN202211693653.3A CN202211693653A CN116103280B CN 116103280 B CN116103280 B CN 116103280B CN 202211693653 A CN202211693653 A CN 202211693653A CN 116103280 B CN116103280 B CN 116103280B
- Authority
- CN
- China
- Prior art keywords
- sample
- solution
- detection
- chromosome
- dna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000001514 detection method Methods 0.000 title claims abstract description 58
- 239000003761 preservation solution Substances 0.000 title claims abstract description 44
- 238000004321 preservation Methods 0.000 title claims abstract description 32
- 210000000349 chromosome Anatomy 0.000 title claims abstract description 30
- 208000036878 aneuploidy Diseases 0.000 title claims abstract description 19
- 231100001075 aneuploidy Toxicity 0.000 title claims abstract description 19
- 238000012216 screening Methods 0.000 title abstract description 8
- 239000000243 solution Substances 0.000 claims abstract description 39
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 36
- 238000000034 method Methods 0.000 claims abstract description 26
- 101710141795 Ribonuclease inhibitor Proteins 0.000 claims abstract description 13
- 102100037968 Ribonuclease inhibitor Human genes 0.000 claims abstract description 13
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 11
- ZNJHFNUEQDVFCJ-UHFFFAOYSA-M sodium;2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid;hydroxide Chemical compound [OH-].[Na+].OCCN1CCN(CCS(O)(=O)=O)CC1 ZNJHFNUEQDVFCJ-UHFFFAOYSA-M 0.000 claims abstract description 9
- 229920004890 Triton X-100 Polymers 0.000 claims abstract description 7
- 108010067770 Endopeptidase K Proteins 0.000 claims abstract description 6
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims abstract description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims abstract description 5
- 108020004414 DNA Proteins 0.000 claims description 37
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 18
- 230000003321 amplification Effects 0.000 claims description 17
- 238000002156 mixing Methods 0.000 claims description 16
- 239000003153 chemical reaction reagent Substances 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 108091005804 Peptidases Proteins 0.000 claims description 7
- 102000035195 Peptidases Human genes 0.000 claims description 7
- 230000014509 gene expression Effects 0.000 claims description 7
- 239000010413 mother solution Substances 0.000 claims description 7
- 235000019833 protease Nutrition 0.000 claims description 7
- 210000004881 tumor cell Anatomy 0.000 claims description 7
- 239000002299 complementary DNA Substances 0.000 claims description 6
- 238000010276 construction Methods 0.000 claims description 6
- 239000012530 fluid Substances 0.000 claims description 5
- 238000012360 testing method Methods 0.000 claims description 5
- 238000003860 storage Methods 0.000 claims description 4
- 238000003776 cleavage reaction Methods 0.000 claims description 3
- 230000007017 scission Effects 0.000 claims description 3
- 238000013518 transcription Methods 0.000 claims description 3
- 230000035897 transcription Effects 0.000 claims description 3
- 230000002103 transcriptional effect Effects 0.000 claims description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
- 210000002308 embryonic cell Anatomy 0.000 claims description 2
- 210000001082 somatic cell Anatomy 0.000 claims description 2
- WQBPSJIAFZCNBR-UHFFFAOYSA-N 2-[2-[2-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCOCCOCCOCCOCCO)C=C1 WQBPSJIAFZCNBR-UHFFFAOYSA-N 0.000 claims 1
- LBCZOTMMGHGTPH-UHFFFAOYSA-N 2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCOCCO)C=C1 LBCZOTMMGHGTPH-UHFFFAOYSA-N 0.000 claims 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 abstract description 22
- 210000001161 mammalian embryo Anatomy 0.000 abstract description 21
- 238000003559 RNA-seq method Methods 0.000 abstract description 19
- 238000001574 biopsy Methods 0.000 abstract description 13
- 238000012163 sequencing technique Methods 0.000 abstract description 13
- 230000008569 process Effects 0.000 abstract description 11
- 108020004707 nucleic acids Proteins 0.000 abstract description 9
- 102000039446 nucleic acids Human genes 0.000 abstract description 9
- 238000010257 thawing Methods 0.000 abstract description 9
- 230000015556 catabolic process Effects 0.000 abstract description 6
- 238000006731 degradation reaction Methods 0.000 abstract description 6
- 238000002474 experimental method Methods 0.000 abstract description 5
- 239000000126 substance Substances 0.000 abstract description 5
- 239000013615 primer Substances 0.000 abstract description 2
- 239000002987 primer (paints) Substances 0.000 abstract description 2
- 238000010353 genetic engineering Methods 0.000 abstract 1
- 239000000523 sample Substances 0.000 description 40
- 239000011324 bead Substances 0.000 description 30
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 22
- 239000000203 mixture Substances 0.000 description 21
- 238000006243 chemical reaction Methods 0.000 description 19
- 238000005119 centrifugation Methods 0.000 description 17
- 102000004190 Enzymes Human genes 0.000 description 15
- 108090000790 Enzymes Proteins 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 14
- 239000006228 supernatant Substances 0.000 description 14
- 230000008439 repair process Effects 0.000 description 12
- 239000007853 buffer solution Substances 0.000 description 11
- 238000013467 fragmentation Methods 0.000 description 10
- 238000006062 fragmentation reaction Methods 0.000 description 10
- 239000000872 buffer Substances 0.000 description 8
- 210000002257 embryonic structure Anatomy 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 230000001052 transient effect Effects 0.000 description 7
- 239000011550 stock solution Substances 0.000 description 6
- 108091070501 miRNA Proteins 0.000 description 5
- 238000003260 vortexing Methods 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 4
- 230000032692 embryo implantation Effects 0.000 description 4
- 239000002679 microRNA Substances 0.000 description 4
- 230000035935 pregnancy Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 101710163270 Nuclease Proteins 0.000 description 3
- 230000002759 chromosomal effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 239000012295 chemical reaction liquid Substances 0.000 description 2
- 238000005336 cracking Methods 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000010355 oscillation Effects 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000001360 synchronised effect Effects 0.000 description 2
- 238000003805 vibration mixing Methods 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000013412 genome amplification Methods 0.000 description 1
- 238000012268 genome sequencing Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000002993 trophoblast Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Plant Pathology (AREA)
- Pathology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Immunology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
原料名称 | 溶液配方(范围) |
Tris-HCl | 20mM-50mM |
EDTA | 1mM-3.5mM |
NaCl | 1mM-4mM |
Triton X-100 | 0.1%-0.5% |
DTT | 5mM-30mM |
Primer | 10μM-20μM |
试剂名称 | 体积(N=反应样本数量) |
缓冲液2 | 30μL×(N+1) |
预扩增酶 | 1μL×(N+1) |
总体积 | 31L×(N+1) |
试剂名称 | 体积(N=反应样本数量) |
缓冲液3 | 30μL×(N+1) |
扩增酶 | 0.8μL×(N+1) |
总体积 | 30.8μL×(N+1) |
温度 | 时间 |
72℃ | 3min |
立即置于冰盒上 | 2min |
试剂名称 | 体积 |
DNA片段化缓冲液 | 1μL |
cDNA | XμL |
无核酸酶水 | (7-X)μL |
总体积 | 8μL |
温度 | 时间 | 循环 |
4℃ | 1min | 1 |
32℃ | 15min | 1 |
65℃ | 30min | 1 |
4℃ | Forever | 1 |
试剂名称 | 体积 |
末端修复缓冲液 | 3.25μL |
末端修复酶 | 1μL |
片段化的DNA | 10μL |
无核酸酶水 | 18.25μL |
总体积 | 32.5μL |
温度 | 时间 | 循环 |
12℃ | 15min | 1 |
37℃ | 15min | 1 |
72℃ | 20min | 1 |
4℃ | Forever | 1 |
试剂名称 | 体积 |
连接缓冲液 | 7μL |
连接酶 | 1μL |
接头 | 1.25μL |
总体积 | 9.25μL |
温度 | 时间 | 循环 |
20℃ | 15min | 1 |
4℃ | Forever | 1 |
细胞系 | 样本编号 | 细胞数量 | 保存液体积 | 保存温度 | 保存时间 |
SK-BR-3 | 1 | 3-5 | 7uL | -20℃ | 15天 |
SK-BR-3 | 2 | 3-5 | 7uL | -20℃ | 15天 |
RT112 | 3 | 3-5 | 7uL | -20℃ | 15天 |
RT112 | 4 | 3-5 | 7uL | -20℃ | 15天 |
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211693653.3A CN116103280B (zh) | 2022-12-28 | 2022-12-28 | 样本保存液及其在染色体非整倍体筛查和/或转录组检测中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211693653.3A CN116103280B (zh) | 2022-12-28 | 2022-12-28 | 样本保存液及其在染色体非整倍体筛查和/或转录组检测中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116103280A CN116103280A (zh) | 2023-05-12 |
CN116103280B true CN116103280B (zh) | 2024-03-15 |
Family
ID=86255445
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211693653.3A Active CN116103280B (zh) | 2022-12-28 | 2022-12-28 | 样本保存液及其在染色体非整倍体筛查和/或转录组检测中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116103280B (zh) |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6204375B1 (en) * | 1998-07-31 | 2001-03-20 | Ambion, Inc. | Methods and reagents for preserving RNA in cell and tissue samples |
CN101999343A (zh) * | 2010-10-26 | 2011-04-06 | 深圳华大基因科技有限公司 | 一种细胞保存液、其制备方法及用途 |
CN105368936A (zh) * | 2015-11-05 | 2016-03-02 | 上海序康医疗科技有限公司 | 一种利用囊胚培养液检测胚胎染色体异常的方法 |
CN111363729A (zh) * | 2020-03-12 | 2020-07-03 | 苏州白垩纪生物科技有限公司 | 一种rna病毒灭活保存液及其应用 |
CN111925941A (zh) * | 2020-09-24 | 2020-11-13 | 北京健为医学检验实验室有限公司 | 一种病毒保存液及其应用 |
CN112626169A (zh) * | 2020-12-28 | 2021-04-09 | 苏州白垩纪生物科技有限公司 | 用于保存生物样本中核酸的样本保存液及其使用方法 |
CN113755556A (zh) * | 2021-09-17 | 2021-12-07 | 深圳海柔思生物医学科技有限公司 | 一种一步法灭活型新冠病毒保存液 |
CN114990106A (zh) * | 2022-06-10 | 2022-09-02 | 序康医疗科技(苏州)有限公司 | 胚胎植入前非整倍体遗传学检测用样本保存液及其制备方法与应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10262755B2 (en) * | 2014-04-21 | 2019-04-16 | Natera, Inc. | Detecting cancer mutations and aneuploidy in chromosomal segments |
-
2022
- 2022-12-28 CN CN202211693653.3A patent/CN116103280B/zh active Active
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6204375B1 (en) * | 1998-07-31 | 2001-03-20 | Ambion, Inc. | Methods and reagents for preserving RNA in cell and tissue samples |
CN101999343A (zh) * | 2010-10-26 | 2011-04-06 | 深圳华大基因科技有限公司 | 一种细胞保存液、其制备方法及用途 |
CN105368936A (zh) * | 2015-11-05 | 2016-03-02 | 上海序康医疗科技有限公司 | 一种利用囊胚培养液检测胚胎染色体异常的方法 |
CN113684250A (zh) * | 2015-11-05 | 2021-11-23 | 序康医疗科技(苏州)有限公司 | 一种利用囊胚培养液检测胚胎染色体异常的方法 |
CN111363729A (zh) * | 2020-03-12 | 2020-07-03 | 苏州白垩纪生物科技有限公司 | 一种rna病毒灭活保存液及其应用 |
CN111925941A (zh) * | 2020-09-24 | 2020-11-13 | 北京健为医学检验实验室有限公司 | 一种病毒保存液及其应用 |
CN112626169A (zh) * | 2020-12-28 | 2021-04-09 | 苏州白垩纪生物科技有限公司 | 用于保存生物样本中核酸的样本保存液及其使用方法 |
CN113755556A (zh) * | 2021-09-17 | 2021-12-07 | 深圳海柔思生物医学科技有限公司 | 一种一步法灭活型新冠病毒保存液 |
CN114990106A (zh) * | 2022-06-10 | 2022-09-02 | 序康医疗科技(苏州)有限公司 | 胚胎植入前非整倍体遗传学检测用样本保存液及其制备方法与应用 |
Non-Patent Citations (1)
Title |
---|
新型冠状病毒保存液开发与应用;余辉等;《现代医药卫生》;20220915;第38卷(第17期);第2989-2992页 * |
Also Published As
Publication number | Publication date |
---|---|
CN116103280A (zh) | 2023-05-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Sha et al. | Dynamics and clinical relevance of maternal mRNA clearance during the oocyte-to-embryo transition in humans | |
Fogarty et al. | Genome editing reveals a role for OCT4 in human embryogenesis | |
US20220403370A1 (en) | Nuclease-based rna depletion | |
Jones et al. | Gene expression profiling of human oocytes following in vivo or in vitro maturation | |
US20100255524A1 (en) | Method for stabilising a biological sample | |
EP2262893B1 (en) | Method for optimized isolation of rna from fixed tissue | |
Vilarino et al. | Mosaicism diminishes the value of pre-implantation embryo biopsies for detecting CRISPR/Cas9 induced mutations in sheep | |
Long et al. | Transcriptome comparisons of multi-species identify differential genome activation of mammals embryogenesis | |
WO2021103784A1 (zh) | 单细胞转录组与翻译组联合测序的多组学方法 | |
CA2626533C (en) | Method for the isolation of mrna from formalin fixed, paraffin-embedded tissue | |
Wu et al. | Transcriptome profiling of laser-captured germ cells and functional characterization of zbtb40 during 17alpha-methyltestosterone-induced spermatogenesis in orange-spotted grouper (Epinephelus coioides) | |
Liu et al. | Remodeling of maternal mRNA through poly (A) tail orchestrates human oocyte-to-embryo transition | |
Wang et al. | The role of DNA methylation reprogramming during sex determination and transition in zebrafish | |
Zhu et al. | Ovarian transcriptomic analysis of Shan Ma ducks at peak and late stages of egg production | |
Du et al. | Single cell RNA-seq reveals genes vital to in vitro fertilized embryos and parthenotes in pigs | |
Alves et al. | Follicular environment as a predictive tool for embryo development and kinetics in cattle | |
Liu et al. | Dynamics of poly (A) tail length and non-A residues during the human oocyte-to-embryo transition | |
CN116103280B (zh) | 样本保存液及其在染色体非整倍体筛查和/或转录组检测中的应用 | |
CN111394799A (zh) | 一种脑膜炎病原体宏基因组二代测序文库的构建方法及其试剂盒 | |
Jukam et al. | Chromatin‐Associated RNA Sequencing (ChAR‐seq) | |
Siles et al. | Big data from small tissues: extraction of high-quality RNA for RNA-sequencing from different oilseed Brassica seed tissues during seed development | |
Dou et al. | Global analysis of DNA methylation in young (J1) and senescent (J2) Gossypium hirsutum L. cotyledons by MeDIP-Seq | |
Martínez‐Moro et al. | RNA‐sequencing reveals genes linked with oocyte developmental potential in bovine cumulus cells | |
Murin et al. | Porcine oocytes matured in a chemically defined medium are transcriptionally active | |
Xiang et al. | Fatty acid metabolism as an indicator for the maternal–to–zygotic transition in porcine IVF embryos revealed by RNA sequencing |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20240311 Address after: 201403 Building 17, No. 26, Lane 1698, Wangyuan Road, Fengxian District, Shanghai Applicant after: YIKON GENOMICS (SHANGHAI) Co.,Ltd. Country or region after: China Applicant after: XUKANG MEDICAL SCIENCE & TECHNOLOGY (SUZHOU) Co.,Ltd. Address before: 201403 Building 17, No. 26, Lane 1698, Wangyuan Road, Fengxian District, Shanghai Applicant before: YIKON GENOMICS (SHANGHAI) Co.,Ltd. Country or region before: China |